Compare Quest Diagnostics Inc (DGX) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs FedEx Corporation — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while FedEx Corporation trades at $291.71 (market cap $69.04B). The key difference: FedEx Corporation is far larger — about 2.7× Quest Diagnostics Inc's market cap, and FedEx Corporation pays the higher dividend (1.67%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and FedEx Corporation for 87 Days on average.
| DGX | FDX | |
|---|---|---|
Market Cap | $25.48B | $69.04B |
Volume | 941,866 | 1,287,367 |
Sector | Health | Industrials |
52-Week High | $247.45 | $339.35 |
52-Week Low | $173.49 | $180.87 |
Typical Hold Time | 56 Days | 87 Days |
Enterprise Value | $31.23B | $98.68B |
Dividend Yield | 1.49% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
FedEx (FDX) trades at $291.73, up 0.93% with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 15.73 and net income margin of 4.68%, though revenue has declined from $93.5B in 2022 to $87.9B in 2025. Recent developments include a $300 million electric truck order and strong shareholder support for management.
Wall Street remains bullish with a $307.55 consensus target (57% buy ratings), but rising fuel costs and competitive pressures pose risks. The stock offers value pricing with P/S of 0.74 and positive cash flow projection for 2026, though technical indicators suggest near-term resistance around $294-299.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
